Subscribe
MacroEcon / Shutterstock.com
27 June 2024NewsAmericasLiz Hockley

Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic

Judges considered Hikma’s label and marketing material when overturning lower court’s decision | Court said Amarin had stated plausible claim for induced infringement of patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug
23 March 2023   Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.
Americas
Amarin appeals ‘skinny label’ loss
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.


Editor's picks

Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024

Editor's picks

Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024
article
Looking back at the UPC’s ‘successful’ first year
4 June 2024
Biotechnology
BioNTech’s patent counsel on fostering groundbreaking innovation
2 May 2024
Careers
USPTO veteran joins Finnegan as of counsel in Washington, DC
2 May 2024

More on this story

Big Pharma
Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug
23 March 2023   Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.
Americas
Amarin appeals ‘skinny label’ loss
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

More on this story

Big Pharma
Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug
23 March 2023   Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.
Americas
Amarin appeals ‘skinny label’ loss
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

More features

Pfizer, Moderna vow appeals after split vaccine ruling
Knobbe Martens partner joins Snell & Wilmer’s Orange County IP practice
UK biotech aims at US rival over genome sequencing technology
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
Earthquake Chevron: A massive shock to the system?
Carpmaels & Ransford expands life sciences partnership
Report reveals boom in digital health patents
Unified Patent Court: The cases, the numbers and what the future holds